Commentary to the new analysis of IMPROVE-IT study concerning achievment of dual goals LDL-cholesterol nad C reactive protein

Abstract

Reduction of LDL-cholesterol below 1.8 mmol/L and hs-CRP below 2 as a marker of inflammation and vascular disease is better attainable by combined therapy statin plus ezetimibe than by statin monotherapy. Reduced cardiovascular morbidity and mortality occur in those patients.

Keywords

• cholesterol
• hs-C reactive protein
• cardiovascular mortality